Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

This study aims to provide a comprehensive understanding of sotorasib's mechanisms of action and resistance in NSCLC patients.

Trial Details

NCT ID
NCT05631249
Phase
PHASE2
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Sotorasib 120Mg Tab
Locations (sample)
  • Lyon, France|45.74906,4.84789
  • Marseille, France|43.29695,5.38107
  • Paris, France|48.85341,2.3488
  • Paris, France|48.85341,2.3488
  • Villejuif, France|48.7939,2.35992

Key Eligibility Criteria

  • Age higher than 18 years;
  • ECOG less or equal to 1 at the time of screening;
  • Pathologically documented, previously treated, locally-advanced and unresectable or metastatic NSCLC with KRAS p.G12C mutation confirmed through mo…
  • Subjects will have progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and un…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →